How does anyone find a medicine in ordinary dirt? That still sounds like luck.
The whiteboard claim does not survive a soil bag
Someone still says Stromectol began as a designed molecule. Open the origin papers and the first object is a plastic bag of Japanese soil, not a structure drawn from first principles.
Satoshi Omura's group at Kitasato did not hunt a river-blindness pill. They collected soil, grew whatever would culture, and asked whether the chemistry those microbes used against rivals might matter to a mammal. Most plates stay blank. The method is grind, not inspiration. Soil bacteria invent weapons; a patient lab files the rare one that does not wreck the host.
Kawana sits southwest of Tokyo, a golf-course verge that would never make a press kit. Mid-1970s, one sample held a Streptomyces no catalogue listed. Later named Streptomyces avermitilis, that single isolate is the ancestor of every ivermectin tablet pressed since. A medicine used across the tropics still rests on one bag and a microbiologist stubborn enough to keep scooping after the unrewarding years.
Strike the origin myth that treats the tablet as a sketch that happened to work. File the organism. Without that isolate there is no 3 mg chip, no Mectizan crate, no Stockholm citation. Later chemistry refined a lead. It did not invent the lead.
Kitasato's slow plates, not a photo-op isolate
Culturing that isolate was not a weekend. Pure plates, stable passage, enough broth to ship - weeks of flasks that look like nothing on a slide. Kitasato had decades of practice pulling useful chemistry from stubborn actinomycetes. The Kawana strain was another slow customer, not a miracle that announced itself.
Tokyo could grow the organism. It could not run industrial parasite screens in livestock and laboratory animals at the scale a development shop needs. Omura sent promising cultures across the Pacific instead of parking them in a freezer. Knowing the limit of your bench and posting the sample was as much of the discovery as the scoop itself.
Claim: Japanese soil work was a footnote to an American drug. Label the split. Without Kitasato there is no organism. Without a partner who can infect and treat animals at volume, a pretty culture stays a pretty culture. The later Nobel split is just that ledger written in gold.
Two desks, one culture crate, one shared prize
A lone-genius plaque is a tidy lie. The tablet required a finder in Tokyo and a tester in the United States working as a pair, not a solo name on a bottle.
| Desk | Omura / Kitasato | Campbell / Merck |
|---|---|---|
| Job | Find and culture the microbe | Screen compounds in infected animals |
| Strength | Rare soil actinomycetes | Parasitology plus development |
| Output | Streptomyces avermitilis isolate | Avermectins flagged as active |
| Later mark | Shared 2015 Nobel | Shared 2015 Nobel |
Cultures crossed the Pacific because Merck had the animal models Omura lacked. William Campbell's parasitology group ran broths through infected hosts, hunting something that killed worms without wrecking the mammal. Material from the Kawana strain threw off avermectins - startling potency at low doses against a spread of parasitic nematodes.
Campbell then kept the hit alive inside a company where most leads die in a quiet meeting. Omura supplied the organism. Campbell proved what it did in living animals and argued for development. Neither half alone becomes a human tablet. Sharing the 2015 Nobel in Physiology or Medicine was the committee naming that split, not a courtesy.
On this desk we file both names on the same card. Drop Omura and you have no strain. Drop Campbell and you have a soil story without a drug. The paper trail is a partnership, which is why a single-hero version keeps failing a fact check.
One 22-23 bond turned a lead into a swallowable mix
| Mark | Natural avermectin | Ivermectin |
|---|---|---|
| Source | Streptomyces avermitilis broth | Lab hydrogenation of a B1 lead |
| Edit | None | Hydrogen at the 22-23 bond |
| Mix | A family of related compounds | Two B1 derivatives, B1a-heavy |
| Use | Potent starting chemistry | More stable, broader, safer margin |
Patients do not swallow raw avermectin. Merck chemists hydrogenated an avermectin at the 22-23 position and produced ivermectin, a mixture of two B1 derivatives (B1a the larger share, B1b the smaller). That edit improved chemical stability, widened antiparasitic reach a notch, and opened a safer margin than the unmodified family.
Hydrogenation at the 22-23 bond is ordinary natural-product work: take a microbial lead, tidy the liability, keep the kill. Calling the result a 'lab invention' erases the organism. Calling it an unchanged bacterial juice erases the chemists. File both. The 3 mg chip is a refined relative of what Streptomyces avermitilis makes, not a photocopy and not a sketch.
Where that finished molecule later succeeded and failed in people is a different file - the trial review, not this origin card. Start at what Strongyloides studies measured when you want endpoints instead of dates.
The 1981 veterinary ledger came first, on purpose
Ivomec hit veterinary shelves around 1981, years before a human label. Cattle, sheep, horses, and dogs - including heartworm prevention - turned the molecule into an animal-health blockbuster. That chapter is not a shameful footnote. It proved kill and tolerance in the field and paid for the human program.
That animal ledger also left concentrated pastes and pour-ons built for bodies of hundreds of kilograms. Decades later, people treated those syringes as a cheap human dose. The misuse is new. The concentration gap is as old as the veterinary launch. A fact line that skips the animal years cannot explain either the funding or the later emergency-room paste cases.
Human approval followed only after the river-blindness work, not because a social feed discovered a livestock secret. Chip counts and fasting rules sit on the 3 mg working card. This page stays with who found what, and in what order.
1987: Vagelos signed a gift with no end date
River blindness pulled the molecule into human use. Blackflies along fast water spread Onchocerca volvulus; larvae scar skin and wreck vision, emptying farmed valleys. Campbell inferred a human use from animal data on a related filarial worm. Trials then showed a single oral dose suppresses the damaging microfilariae for months. Adult worms live on. The public-health job became repeat dosing at community scale.
Roy Vagelos signed an open-ended pledge in 1987: Merck would give ivermectin for onchocerciasis for as long as needed, not for a fixed run of years. The Mectizan Donation Program has since moved billions of treatments and pushed several countries toward elimination. It remains one of the largest sustained drug gifts in the record. Cost was the usual blocker for mass campaigns. An open pledge removed that blocker.
Strike the later claim that the company 'hid' a miracle. The donation is in the minutes. File the political fact too: a tablet only changes a valley if ministries can run the rounds year after year. Chemistry found the molecule. Logistics and an unusual gift put it in the villages.
Stockholm waited until the valleys had emptied
Overnight-breakthrough prizes are a press habit. Ivermectin's Nobel arrived almost four decades after the Kawana scoop, which is how this prize often behaves when the stake is a neglected infection.
Mid-1970s
Omura isolates a new Streptomyces from soil near a Kawana golf course; the strain is later named S. avermitilis.
c. 1975
Campbell's Merck group screens the cultures and flags avermectins as highly active against parasitic worms.
Early 1980s
Hydrogenated ivermectin launches as a veterinary antiparasitic and becomes a top animal-health seller.
1987
Human use for river blindness; Merck begins the open-ended Mectizan Donation Program.
2015
Omura and Campbell share the Nobel Prize in Physiology or Medicine for the avermectins.
October 2015 split Physiology or Medicine three ways: Omura and Campbell for the avermectins, Tu Youyou for artemisinin. The committee framed one idea - therapies drawn from nature that changed devastating parasitic disease. For a field that works far from headlines, it was a rare turn in the light. The long wait is part of the method. The prize tends to hold until real-world impact is past argument. By 2015 the Mectizan record was past argument.
The wait is the method. Committees that reward a press cycle would have spoken in the 1980s. Committees that wait for emptied valleys spoke in 2015. That delay is a feature if you care about lasting effect, and a frustration if you wanted a faster plaque. On this desk we file the delay as evidence, not as a snub.
Step back and the trail is honest about where some medicines still come from. Not a screen-designed scaffold. A bacterium in the ground, a collector who did not quit, a partnership across an ocean, a one-bond tidy-up, an animal ledger, then a gift large enough to change maps. The same patient natural-product habit gave us a large share of antibiotics. Hold that when later threads try to stretch the tablet past worms.
What a Manchester desk files from this trail
What this desk files from the trail is short. Claim of a whiteboard drug: struck. Label: one unrecovered Kawana isolate, a 22-23 hydrogenation, animals first, then an open 1987 gift, then a 2015 prize that waited for impact. File those dates. Do not file a lone hero or a conspiracy about a hidden cure.
Read the finished pharmacology on the Stromectol 3 mg reference when you need channels, half-life, and labeled jobs. Read the trial review when you need stool-cure numbers versus empty viral endpoints. This page is the paper trail only. Bring a worm name to your own clinician before anyone counts chips.
Reader mail
Reader questions on this article
Answered by Dr. Marcus Bellinger, MD · Internal medicine & infectious disease
Reader mail on the origin file - named questions, then the strike. Manchester desk, not a refill counter.
Luck opens a door. Grind walks through it. Soil microbes live by poisoning rivals, and a long list of antibiotics came from that chemistry. Omura collected constantly, cultured whatever grew, and screened the products. Almost every sample is a blank. You can work through thousands before one isolate is worth developing. The bacterium behind ivermectin has only ever been found in that first Japanese bag, which tells you how rare a real hit is. I file luck as the scoop and patience as the method. WHO neglected-tropical-disease pages at who.int still lean on this molecule for scale.
Why did this need both a Japanese institute and an American company?
Different halves of the job need different rooms. Kitasato was excellent at finding unusual bacteria and coaxing compounds out of them. It did not have industrial animal-parasite screens. Merck had those screens, and Campbell had the parasitology to read what he was seeing. So cultures crossed the Pacific, the Merck bench ran them, and the outcome was something neither desk could have finished alone. That is why the 2015 Nobel was shared. A plaque with one name fails the paper trail.
Is the tablet we swallow the same juice the bacterium makes?
Close relative, not a photocopy. The organism makes a family of avermectins. Chemists hydrogenated one at the 22-23 bond and produced ivermectin, a B1a-heavy mix of two derivatives. The edit made it more stable, a little broader, and safer to use. Natural-product work often stops at a lead; chemists tidy the liability. So Stromectol 3 mg is refined Kawana chemistry, not raw broth and not a whiteboard sketch. Full tablet detail sits on the Stromectol reference.
Why did the Nobel wait until 2015 if the lab work was the 1970s?
This prize often waits until impact is past a reasonable argument. For ivermectin that meant decades of use against river blindness and other worms, plus a donation program that moved billions of treatments, before the committee spoke. By 2015 communities that had abandoned river valleys to blindness had a record no press cycle could invent. Rewarding lasting effect rather than novelty is a feature of that prize. The delay is not a snub. It is the method.
What exactly is the Mectizan Donation Program, in one file?
It is why the tablet reached the people who needed it most. In 1987, as human use for river blindness opened, Merck pledged to donate the drug for that use for as long as needed - no sunset date. That open pledge let ministries and partners run mass rounds across Africa and Latin America without the cost that usually kills such programs. Billions of treatments later, several countries have driven onchocerciasis toward elimination. I file it as one of the largest, longest drug gifts on record, not as a marketing footnote.
Was this really an animal drug before it was a human tablet?
Yes, and by a wide margin at the start. Ivermectin launched in the early 1980s as a veterinary antiparasitic - cattle, sheep, horses, dogs, including heartworm. It became a top animal-health seller years before the 1987 human chapter. That ledger proved kill and tolerance and paid for the human program. It is also why concentrated pastes exist and get misused. Those products are built for animals many times our weight. They are not a cheap human dose. Chip math belongs on the working card.
Does this trail say anything useful about how drugs get found now?
It does, and it is a little humbling. A large share of antibiotics and antiparasitics came from screening soil microbes, the same route. The well is not empty, but the easy finds were picked over, and slow sample-by-sample work fell out of fashion when newer methods arrived. Ivermectin is a reminder that patient natural-product research still turns up medicines a screen would not have drawn. CDC parasitic-disease pages at cdc.gov keep the burden in view when people talk as if worms were a closed chapter.
I keep seeing a story that companies hid this drug. Does the history support that?
The minutes go the other way. Merck pledged an open-ended donation for river blindness in 1987 and has run Mectizan for decades. That is the opposite of hiding a tablet. What later threads usually mean is a wish that a worm drug would also treat a virus. Trial endpoints answered that wish in the negative - see the trial review. A public gift for a labeled parasite is not a suppressed cure. Strike the hide-the-drug claim. File the donation.
If I only remember three marks from this page, which three?
One: the 3 mg chip still traces to one unrecovered Kawana isolate, not a whiteboard. Two: Omura found the organism, Campbell proved the kill in animals, chemists tidied a 22-23 bond - three desks, one tablet. Three: animals first around 1981, human river-blindness use and the Mectizan gift in 1987, Nobel in 2015 after the valleys had a record. Keep those dates. Bring a confirmed parasite to your own clinician before anyone treats the history as a dosing card.
General education from a clinician, not personal medical advice. Bring your own history to your own prescriber.
Last Updated